Eton Pharmaceuticals Inc

+0.10 (+1.24%)
Earnings Announcements

Eton Pharma Reports Q3 2020 Financial Results

Published: 11/12/2020 21:38 GMT
Eton Pharmaceuticals Inc (ETON) - Eton Pharmaceuticals Announces Third Quarter 2020 Financial Results.
Eton Pharmaceuticals Inc - Anticipates Having Commercial Availability of Alkindi Sprinkle by End of November.
Eton Pharmaceuticals Inc - Remains on Schedule to File a Prior Approval Supplement for Biorphen Vials in Q4 of 2020.
Eton Pharmaceuticals - As of September 30, 2020, Reported Cash, Equivalents of $7.3 Million.
Eton Pharmaceuticals - Qtrly Loss per Share $0.31.
Revenue is expected to be $3.44 Million
Adjusted EPS is expected to be -$0.21

Next Quarter Revenue Guidance is expected to be $5.52 Million
Next Quarter EPS Guidance is expected to be -$0.20

More details on our Analysts Page.